Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (72 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > TLT is entering new markets $$$...
View:
Post by wildbird1 on Jul 01, 2024 11:25am

TLT is entering new markets $$$...

Up until now TLT market potential $value was almost exclusively...Bladder Cancer market=$5 Billion/year.

Lately 3 more very lucrative markets have been added(because of ''Combination Therapy'').
1) Chemotherapy Cancer market= $157 billion/year.
2) Lung Cancer market                = $ 29 billion/year.
3) Immunotherapy cancer market= $126 billion/year.

When TLT will sign one(or more) Big Pharma deal, these ''Combinaison Therapy''  potential $value will certainly be discussed.

The future looks great.
Comment by Alamir1111 on Jul 01, 2024 11:39am
Got any estimate about how much pp will bring in  ?
Comment by plantrader on Jul 01, 2024 11:48am
It really is exciting. The catch is, #1-3 lucrative markets are all still only preclinical. Isn't there a long history of companies showing amazing preclinical results and then not being able to translate that to bring a product to market? Let's hope a BP will extrapolate some of that into actual value, in advance, due to the fact that Ruvidar appears to work great on bladder cancer in ...more  
Comment by Galaxym31 on Jul 01, 2024 12:00pm
Wow so much money , can we see 60 cents .
Comment by Galaxym31 on Jul 01, 2024 12:26pm
so I can recover my warrant monies .
Comment by chry200030 on Jul 01, 2024 3:02pm
Not looking for pennies here, looking for dollars. Yes, we may see .60 but so what... I'm looking for 60 dollars. It won't come tomorrow, but it will come..  Let the financing close, then let's see what happens in the New Year... Buy and hold :-)
Comment by Gooseybear on Jul 01, 2024 3:13pm
I think finally there will be a break of epic proportion. I've been long since 2017. 
Comment by Legit62 on Jul 01, 2024 7:10pm
Gooseybear, im right there with you, when this runs, it will be epic, getting close. Lets see how rest of week plays out once we get our financing news
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250



USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse